<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>WW International, Inc. (WW)，一家减肥解决方案提供商，周四表示，它现在通过其 Med+ 项目和相关医疗集团提供对礼来的新批准口服 GLP-1 药物 Foundayo 的访问，扩展了肥胖或超重人群的治疗选择。</p>
<p>该公司表示，符合条件的会员可以在获得经过认证的临床医生支持、保险协助以及其 GLP-1 成功计划的指导下，使用这种每日一次、无需注射的疗法，该计划在治疗前、治疗中和治疗后提供指导。</p>
<p>WW International 补充说，自费患者的最低剂量价格将从每月 149 美元起，具体费用因剂量而异。</p>
<p>“通过这一新产品，Weight Watchers 正在通过一个值得信赖的平台扩展对 FDA 批准的新选择的访问，旨在帮助会员获得临床支持和持续指导，” Weight Watchers 首席商业官 Scott Honken 表示。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

LLYZ

2 倍做多 LLY ETF - Defiance

礼来

WGHTQ

2 倍做多 LLY ETF - Direxion

<p>WW International, Inc. 宣布将礼来的新批准口服 GLP-1 药物 Foundayo 纳入其 Med+ 计划。该计划旨在为肥胖或超重的个体提供更多治疗选择。符合条件的会员可以获得这种每日一次的治疗，以及来自认证临床医生的支持和 GLP-1 成功计划。自费患者的定价从每月 149 美元起，具体费用根据剂量而异。首席商业官 Scott Honken 强调了这一新产品在为会员提供临床支持和指导方面的重要性</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>WW International, Inc. (WW), a weight loss solutions provider, on Thursday said it is now offering access to Eli Lilly and Company's newly approved oral GLP-1 drug Foundayo through its Med+ program and affiliated medical groups, expanding treatment options for people with obesity or overweight.</p>
<div class="lb-trans"><p>WW International, Inc. (WW)，一家减肥解决方案提供商，周四表示，它现在通过其 Med+ 项目和相关医疗集团提供对礼来的新批准口服 GLP-1 药物 Foundayo 的访问，扩展了肥胖或超重人群的治疗选择。</p>
</div><p>The company said eligible members can access the once-daily, injection-free therapy alongside support from board-certified clinicians, insurance assistance and its GLP-1 Success program, which provides guidance before, during and after treatment.</p>
<div class="lb-trans"><p>该公司表示，符合条件的会员可以在获得经过认证的临床医生支持、保险协助以及其 GLP-1 成功计划的指导下，使用这种每日一次、无需注射的疗法，该计划在治疗前、治疗中和治疗后提供指导。</p>
</div><p>WW International added that pricing for self-pay patients will start at $149 per month for the lowest dose, with costs varying by dosage.</p>
<div class="lb-trans"><p>WW International 补充说，自费患者的最低剂量价格将从每月 149 美元起，具体费用因剂量而异。</p>
</div><p>&#34;With this new offering, Weight Watchers is expanding access to a new FDA-approved option through a trusted platform built to help members access treatment with clinical support and ongoing guidance,&#34; said Scott Honken, Chief Commercial Officer at Weight Watchers.</p>
<div class="lb-trans"><p>“通过这一新产品，Weight Watchers 正在通过一个值得信赖的平台扩展对 FDA 批准的新选择的访问，旨在帮助会员获得临床支持和持续指导，” Weight Watchers 首席商业官 Scott Honken 表示。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

WW 国际将礼来的 GLP-1 Foundayo 纳入其 Med+ 计划